Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

Abstract

When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival. (ClinicalTrials.gov number, NCT00083551.).